First Patient Dosed in Phase 3 Trial Testing VB-111 in Platinum-resistant Ovarian Cancer

First Patient Dosed in Phase 3 Trial Testing VB-111 in Platinum-resistant Ovarian Cancer
VBL Therapeutics has successfully administered the initial dose to the first patient in its Phase 3 trial investigating the effects of VB-111 (ofranergene obadenovec) in platinum-resistant ovarian cancer. The pivotal OVAL trial (NCT03398655), currently recruiting adult patients, will compare the effectiveness of VB-111 and Taxol (paclitaxel) against Taxol alone in women who failed to respond to prior platinum-based chemotherapy. The trial is expected to enroll 350 patients from 70 clinical sites in the United States and Israel. For more information, click on the clinical trial registration number above. VB-111 is a first-in-class anticancer agent that targets tumors through a dual mechanism. In addition to delivering a gene therapy that eliminates a tumor's blood supply, the viral vector where the gene is inserted induces specific immune responses that lead to cancer cell death. OVAL's primary goal is to determine whether the addition of VB-111 to Taxol improves patients' overall survival. Additional (secondary) endpoints include the proportion of patients who respond to the treatment, and the time to disease progression or death. Patient-reported outcome measures will also be assessed. In a previous Phase 1/2 trial, combining a therapeutic dose of VB-111 with chemotherapy significantly increased survival times, compared to a low VB-111 dose – 810 days vs. 172 days. Also, VB-111 r
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *